Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)

Introduction: Monoclonal antibodies (mAbs) targeting immunoglobulin E (IgE) [omalizumab], type 2 (T2) cytokine interleukin (IL) 5 [mepolizumab, reslizumab], IL-4 Receptor (R) α [dupilumab], and IL-5R [benralizumab]), improve quality of life in patients with T2-driven inflammatory diseases. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pera, Victor, Brusselle, Guy G., Riemann, Sebastian, Kors, Jan A., Van Mulligen, Erik M., Parry, Rowan, de Wilde, Marcel, Rijnbeek, Peter R., Verhamme, Katia M. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682182/
https://www.ncbi.nlm.nih.gov/pubmed/38035014
http://dx.doi.org/10.3389/fphar.2023.1276340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682182/
https://www.ncbi.nlm.nih.gov/pubmed/38035014
http://dx.doi.org/10.3389/fphar.2023.1276340

Ejemplares similares